Introduction & background
Company Presentation
Staff
 
Ongoing Projects
Marketed Products
CRO Services
About us
Technology
Products & Services
R&D Structure
Commercial Targets
  Contact us
News


11/14/2012
Rivastigmine Patch for LATAM markets

Amarin Technologies S.A. has licensed its Rivastigmine Patch to Asofarma S.A., for Brazil and Argentina markets.

Registration is expected to be accomplished during 2013.

Rivastigmine patch is a drug-in-adhesive transdermal system which inhibits the cholinesterase activity and is indicated for the treatment of Alzheimer disease and Parkinson's disease dementia.

[+]

 

12/14/2010
Helm AG Aquires Shares in Amarin Technologies S.A.

Hamburg, December 10th, 2010[+]

 

10/6/2011
New Building for Amarin Technologies S.A.

[+]

 

9/22/2009
Relocation and new logo

The Board of Directors of Amarin Technologies SA announces a new stage in the Company strategies and targets.
Amarin has acquired a building in Buenos Aires city where the Company will increase and [+]

 

8/5/2009
Fentanyl TDS New Markets

Amarin Technologies S.A. is proud to announce that Fentanyl TDS is being exported to Taiwan (as Fentanyl HPQ, for Bio-Pro), since March 2009, and France (as Fentanyl Biogaran, for Biogaran), since [+]

 

11/29/2008
New Fentanyl TDS Approvals & Brand Names

Fentanyl TDS received approval from the United [+]

 

6/28/2008
Dolforin®, a new brand for Fentanyl TDS

The transdermal delivery system Fentanyl TDS wa [+]

 

6/30/2007
Fentanyl TDS, Launched in Germany

[+]

 
Intro & Background | Presentation | Staff
Site Map | Legal Statement
Amarin Technologies S.A. © 2017   Design & Development: Mandarina